2023
Tissue-specific biological aging predicts progression in prostate cancer and acute myeloid leukemia
Ramakrishnan A, Datta I, Panja S, Patel H, Liu Y, Craige M, Chu C, Jean-Marie G, Oladoja A, Kim I, Mitrofanova A. Tissue-specific biological aging predicts progression in prostate cancer and acute myeloid leukemia. Frontiers In Oncology 2023, 13: 1222168. PMID: 37746266, PMCID: PMC10512286, DOI: 10.3389/fonc.2023.1222168.Peer-Reviewed Original ResearchAcute myeloid leukemiaProstate cancerYears of ageAML progressionCancer progressionMyeloid leukemiaStratified survival analysisBiological agingHigh Gleason scoreCox proportional hazardsMarker of progressionProstate cancer progressionPersonalized therapeutic managementMultiple cancer typesAML incidenceOverall survivalPrognostic factorsGleason scoreTherapeutic managementPatient cohortRisk scorePatientsCancer aggressivenessChronological agingProportional hazards
2022
PD03-07 ASSOCIATION BETWEEN ADVERSE SURGICAL PATHOLOGY AND OVERALL SURVIVAL AMONG PATIENTS WITH LOW-RISK PROSTATE CANCER
Lee G, Lee E, Leopold Z, Kim S, Leapman M, Kim I. PD03-07 ASSOCIATION BETWEEN ADVERSE SURGICAL PATHOLOGY AND OVERALL SURVIVAL AMONG PATIENTS WITH LOW-RISK PROSTATE CANCER. Journal Of Urology 2022, 207: e44. DOI: 10.1097/ju.0000000000002518.07.Peer-Reviewed Original Research
2021
Facility-Level Variation in Use of Locoregional Therapy for Metastatic Prostate Cancer
Buck M, Ghiraldi E, Demkowicz P, Park H, An Y, Kann B, Yu J, Sprenkle P, Kim I, Leapman M. Facility-Level Variation in Use of Locoregional Therapy for Metastatic Prostate Cancer. Urology Practice 2021, 9: 141-149. PMID: 37145694, DOI: 10.1097/upj.0000000000000290.Peer-Reviewed Original ResearchMetastatic prostate cancerLocal therapyProstate cancerLocoregional therapyFacility-level useFacility-level variationM1 prostate cancerDefinitive local therapyNational Cancer DatabaseMetastatic prostate adenocarcinomaClinical practice guidelinesMultilevel logistic regressionM1 diseasePatient factorsTherapy useUninsured statusRadical prostatectomyCancer DatabaseProstate adenocarcinomaHigh comorbidityLocal treatmentPatient levelPractice guidelinesLower oddsPatientsMarginal improvement in survival among patients diagnosed with metastatic prostate cancer in the second‐line antiandrogen therapy era
Kim I, Jang T, Kim S, Lee D, Kim D, Singer E, Ghodoussipour S, Stein M, Aron M, Dall’Era M, Kim I. Marginal improvement in survival among patients diagnosed with metastatic prostate cancer in the second‐line antiandrogen therapy era. Cancer Medicine 2021, 10: 7909-7920. PMID: 34713977, PMCID: PMC8607264, DOI: 10.1002/cam4.4074.Peer-Reviewed Original ResearchConceptsMetastatic prostate cancerMetastatic prostate cancer patientsProstate cancer patientsProstate cancerCancer patientsSecond-line antiandrogen therapyProstate cancer-specific survivalCancer-specific survivalNew treatment agentsTherapy eraVisceral metastasesAntiandrogen therapySEER databaseSurvival benefitSurvival outcomesPatientsCancerSurvivalTreatment agentsMenMetastasisTherapyMonthsAbrogation of survival disparity between insured and uninsured individuals after the USPSTF's 2012 prostate-specific antigen-based prostate cancer screening recommendation.
Kim I, Kim D, Kim S, Singer E, Jang T, Ghodoussipour S, Aron M, Kim I. Abrogation of survival disparity between insured and uninsured individuals after the USPSTF's 2012 prostate-specific antigen-based prostate cancer screening recommendation. Journal Of Clinical Oncology 2021, 39: 77-77. DOI: 10.1200/jco.2020.39.28_suppl.77.Peer-Reviewed Original ResearchProstate cancer-specific survivalU.S. Preventive Services Task ForceSurvival disparitiesUninsured patientsSocioeconomic quintileProstate cancerInsurance statusMarital statusWorse prostate cancer-specific survivalProstate cancer screening recommendationsCox proportional hazards modelDiagnostic time periodsCancer-specific survivalCancer screening recommendationsProportional hazards modelProstate-specific antigenScreening recommendationsSurvival outcomesInsured patientsWorse outcomesHazards modelPatientsBetter outcomesMedian household incomeUninsured individualsTranscription factor 4 expression in circulating tumor cells from castration‐resistant prostate cancer
Nagaya N, Lee G, Lu Y, Ashizawa T, Nagata M, Kim I, Horie S. Transcription factor 4 expression in circulating tumor cells from castration‐resistant prostate cancer. IJU Case Reports 2021, 4: 159-162. PMID: 33977248, PMCID: PMC8088892, DOI: 10.1002/iju5.12272.Peer-Reviewed Original ResearchCastration-resistant prostate cancerTranscription factor 4Prostate cancerTumor cellsAntiandrogen therapyNeuroendocrine differentiationFactor 4Group of patientsTranscription factor 4 expressionMessenger ribonucleic acid expressionFactor 4 expressionRibonucleic acid expressionChemotherapy treatmentPatientsDrug resistanceTherapyCancerChemotherapyCellsExpressionPhysiciansEffects of MTX-23, a Novel PROTAC of Androgen Receptor Splice Variant-7 and Androgen Receptor, on CRPC Resistant to Second-Line Antiandrogen Therapy
Lee G, Nagaya N, Desantis J, Madura K, Sabaawy H, Kim W, Vaz R, Cruciani G, Kim I. Effects of MTX-23, a Novel PROTAC of Androgen Receptor Splice Variant-7 and Androgen Receptor, on CRPC Resistant to Second-Line Antiandrogen Therapy. Molecular Cancer Therapeutics 2021, 20: 490-499. PMID: 33277442, DOI: 10.1158/1535-7163.mct-20-0417.Peer-Reviewed Original ResearchConceptsCastration-resistant prostate cancerSecond-line antiandrogen therapyAR full lengthAndrogen receptor splice variant 7AR-V7Antiandrogen therapyAndrogen-responsive prostate cancer cellsProstate cancer cellular proliferationHuman prostate cancer cell linesProstate cancer cell linesStandard of careCancer cellular proliferationCellular proliferationPotential therapeutic valueProstate cancer cellsAgents abirateroneCancer cell linesProteolysis Targeting ChimerasMechanisms of resistanceAndrogen receptorAR DNAProstate cancerTumor growthTherapeutic valueAntiproliferative effectsTrends in the use of administrative databases in urologic oncology: 2000 – 2019.
Leopold Z, Dave P, Menon A, Patel H, Srivastava A, Kim I, Jang T, Singer E. Trends in the use of administrative databases in urologic oncology: 2000 – 2019. Journal Of Clinical Oncology 2021, 39: 356-356. DOI: 10.1200/jco.2021.39.6_suppl.356.Peer-Reviewed Original ResearchNational Surgical Quality Improvement ProgramPremier Healthcare DatabaseNational Cancer DatabaseNationwide Inpatient SampleAdministrative databasesUrologic oncologySEER-MedicareSurgical Quality Improvement ProgramStudy periodEnd Results (SEER) databaseQuality Improvement ProgramRepresentative study populationComparative effectiveness researchResults databaseGenitourinary malignanciesInpatient SampleBladder cancerCancer DatabaseProstate cancerInclusion criteriaStudy populationTreatment trendsAD useHealthcare databasesLarger sample sizeQuantifying publication rates and time to publication for urologic oncology podium presentations.
Mikhail M, Chua K, Patel H, Tabakin A, Doppalapudi S, Ghodoussipour S, Kim I, Jang T, Srivastava A, Singer E. Quantifying publication rates and time to publication for urologic oncology podium presentations. Journal Of Clinical Oncology 2021, 39: 357-357. DOI: 10.1200/jco.2021.39.6_suppl.357.Peer-Reviewed Original ResearchPodium presentationsAmerican Urological Association annual meetingsFull-length manuscriptsPeer-reviewed journalsMedian timeBladder cancerProstate cancerUrologic oncologyMedian journal impact factorPublication rateAnnual MeetingPresentationCancerPresentation abstractsAUA meetingMatching publicationsMeeting attendanceManuscript publicationConclusionAUA Annual MeetingJournal impact factorUnpublished researchAssociation Annual MeetingRelationship communication and the course of psychological outcomes among couples coping with localised prostate cancer
Manne S, Kashy D, Myers‐Virtue S, Zaider T, Kissane D, Heckman C, Kim I, Penedo F, Lee D. Relationship communication and the course of psychological outcomes among couples coping with localised prostate cancer. European Journal Of Cancer Care 2021, 30: e13401. PMID: 33586282, PMCID: PMC9165020, DOI: 10.1111/ecc.13401.Peer-Reviewed Original ResearchConceptsBetter psychological outcomesPsychological outcomesPoor psychological outcomesRelationship communicationCancer-specific distressMeasures of communicationMutual avoidancePsychological adjustmentCommunication variablesCommunication trainingCancer concernsEffective interventionsGood communicationDepressive symptomsHigher disclosureProstate cancerImportant predictorPredictive rolePositive standingAvoidancePositive directionProstate cancer patientsSpousesMore researchGreater focusTrends in the use of administrative databases in urologic oncology: 2000–2019
Leopold Z, Dave P, Menon A, Patel H, Srivastava A, Kim I, Jang T, Singer E. Trends in the use of administrative databases in urologic oncology: 2000–2019. Urologic Oncology Seminars And Original Investigations 2021, 39: 487-492. PMID: 33551250, DOI: 10.1016/j.urolonc.2021.01.014.Peer-Reviewed Original ResearchConceptsAdministrative databasesUrologic oncologyNational Surgical Quality Improvement ProgramSurgical Quality Improvement ProgramPremier Healthcare DatabaseEnd Results (SEER) databaseNational Cancer DatabaseNationwide Inpatient SampleQuality Improvement ProgramRepresentative study populationComparative effectiveness researchGenitourinary malignanciesResults databaseSEER-MedicareInpatient SampleBladder cancerCancer DatabaseProstate cancerInclusion criteriaStudy populationTreatment trendsAD useHealthcare databasesLarger sample sizeStudy period
2020
RNA-seq profile of African American men with a clinically localized prostate cancer
Nagaya N, Rosenfeld J, Lee G, Kim I. RNA-seq profile of African American men with a clinically localized prostate cancer. Prostate International 2020, 9: 125-131. PMID: 34692584, PMCID: PMC8498718, DOI: 10.1016/j.prnil.2020.11.002.Peer-Reviewed Original ResearchProstate cancer tissuesProstate cancerAfrican American menAA menCA menCancer tissuesPotential genetic risk factorSphingosine-1-phosphate signalingAmerican menExpression levelsGenetic risk factorsIngenuity Pathway AnalysisPathway analysisRNA sequencingPoor prognosisBiochemical recurrenceRadical prostatectomyRisk factorsLow expressionCancerMenCaucasiansSignificant differencesPatientsHigh rateObservation with or without late radiotherapy is equivalent to early radiotherapy in high-risk prostate cancer after radical prostatectomy: A SEER-Medicare analysis on trends, survival outcomes, and complications
Kwon Y, Wang W, Srivastava A, Jang T, Singer E, Parikh R, Kim W, Kim I. Observation with or without late radiotherapy is equivalent to early radiotherapy in high-risk prostate cancer after radical prostatectomy: A SEER-Medicare analysis on trends, survival outcomes, and complications. Prostate International 2020, 9: 82-89. PMID: 34386450, PMCID: PMC8322776, DOI: 10.1016/j.prnil.2020.10.002.Peer-Reviewed Original ResearchHigh-risk prostate cancerLate radiotherapyDRT groupProstate cancerSurvival outcomesHigh-risk pathologic featuresMultivariable Cox regression modelsCancer-specific survival outcomesFive-year overallPost-RP radiotherapySEER-Medicare analysisMonths of surgeryWorse survival outcomesKaplan-Meier analysisCox regression modelProportion of menCochran-Armitage trend testEarly radiotherapyPathologic featuresRegression modelsStudy cohortERT groupRadical prostatectomyClinical trialsRadiation toxicityCXC Chemokine/Receptor Axis Profile and Metastasis in Prostate Cancer
Nagaya N, Lee G, Horie S, Kim I. CXC Chemokine/Receptor Axis Profile and Metastasis in Prostate Cancer. Frontiers In Molecular Biosciences 2020, 7: 579874. PMID: 33195424, PMCID: PMC7593595, DOI: 10.3389/fmolb.2020.579874.Peer-Reviewed Original ResearchLymph node metastasisPrimary prostate cancerChemokines/receptorsMetastatic prostate cancerNode metastasisProstate cancerReceptor expressionMetastatic sitesChemokine/receptor axisMultivariate logistic regression analysisLog-rank test resultsLogistic regression analysisCancer Genome AtlasBone metastasesIndependent predictorsLymph nodesPostoperative recurrenceDistant metastasisCXCL10 expressionMRNA expression dataReceptor axisMetastasisTeam databaseLow expressionCancer progressionAbrogation of survival disparity between Black and White individuals after the USPSTF′s 2012 prostate‐specific antigen–based prostate cancer screening recommendation
Kim I, Jang T, Kim S, Modi P, Singer E, Elsamra S, Kim I. Abrogation of survival disparity between Black and White individuals after the USPSTF′s 2012 prostate‐specific antigen–based prostate cancer screening recommendation. Cancer 2020, 126: 5114-5123. PMID: 32888321, DOI: 10.1002/cncr.33179.Peer-Reviewed Original ResearchConceptsUS Preventive Services Task ForceProstate cancerSurvival disparitiesWhite menProstate cancer screening recommendationsBlack menPCa-specific survivalAdverse clinical featuresCancer screening recommendationsEnd Results (SEER) databaseYear of diagnosisProstate-specific antigenClinical featuresScreening recommendationsResults databaseSurvival outcomesGrade CGrade D.White individualsMenRacial discrepanciesSurvivalTask ForceOutcomesTotalThe cytoreductive prostatectomy in metastatic prostate cancer: what the individual trials are hoping to answer
Ranasinghe W, Chapin B, Kim I, Sooriakumaran P, Lawrentschuk N. The cytoreductive prostatectomy in metastatic prostate cancer: what the individual trials are hoping to answer. BJU International 2020, 125: 792-800. PMID: 32176456, DOI: 10.1111/bju.15055.Peer-Reviewed Original ResearchConceptsHormone-sensitive metastatic prostate cancerMetastatic prostate cancerCytoreductive prostatectomyAndrogen deprivation therapyProstate cancerOverall survivalRadical prostatectomyLimited bone metastasesCancer-specific outcomesLocal treatment optionsProgression-free survivalDiagnosis of metastasisPrimary outcome measureNovel treatment algorithmOligometastatic settingAdjuvant treatmentMetastatic settingSecondary endpointsCastration resistanceMetastatic diseaseStandard therapyBone metastasesDefinitive treatmentOngoing trialsTreatment algorithmIndividual and joint effects of metformin and statins on mortality among patients with high‐risk prostate cancer
Tan X, E J, Lin Y, Rebbeck T, Lu S, Shang M, Kelly W, D'Amico A, Stein M, Zhang L, Jang T, Kim I, Demissie K, Ferrari A, Lu‐Yao G. Individual and joint effects of metformin and statins on mortality among patients with high‐risk prostate cancer. Cancer Medicine 2020, 9: 2379-2389. PMID: 32035002, PMCID: PMC7131852, DOI: 10.1002/cam4.2862.Peer-Reviewed Original ResearchConceptsHigh-risk PCaPCa mortalityCause mortalityPopulation-based retrospective cohort studyHigh-risk prostate cancerCox proportional hazards modelRetrospective cohort studyHigh-risk patientsFirst human studyProstate cancer metastasisCause of deathProportional hazards modelPre-clinical studiesMetformin useCohort studyProstate cancerStatinsHazards modelHuman studiesPatientsMetforminSignificant associationMortalityPropensity scoreCancer metastasis
2019
TCF4 induces enzalutamide resistance via neuroendocrine differentiation in prostate cancer
Lee G, Rosenfeld J, Kim W, Kwon Y, Palapattu G, Mehra R, Kim W, Kim I. TCF4 induces enzalutamide resistance via neuroendocrine differentiation in prostate cancer. PLOS ONE 2019, 14: e0213488. PMID: 31536510, PMCID: PMC6752758, DOI: 10.1371/journal.pone.0213488.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBenzamidesBeta CateninCell Line, TumorDisease Models, AnimalDrug Resistance, NeoplasmHumansMaleMiceMice, KnockoutNeuroendocrine CellsNitrilesPhenylthiohydantoinProstatic NeoplasmsProtein BindingProtein TransportTranscription Factor 7-Like 2 ProteinXenograft Model Antitumor AssaysConceptsCastration-resistant prostate cancerEnzalutamide resistanceTranscription factor 4Neuroendocrine differentiationProstate cancerSecond-generation androgen receptor antagonistHuman prostate cancer cell linesLNCaP human prostate cancer cell lineResistant prostate cancerProstate cancer cell linesStandard of careAndrogen receptor antagonistMouse xenograft modelExpression levelsCell linesTCF4 overexpressionCancer cell linesMedian timeClinical benefitReceptor antagonistNeuroendocrine markersMetastatic CaPTreatment resistanceXenograft modelParental cell lineDihydrotestosterone Increases Cytotoxic Activity of Macrophages on Prostate Cancer Cells via TRAIL
Lee G, Kim J, Kwon S, Stein M, Hong J, Nagaya N, Billakanti S, Kim M, Kim W, Kim I. Dihydrotestosterone Increases Cytotoxic Activity of Macrophages on Prostate Cancer Cells via TRAIL. Endocrinology 2019, 160: 2049-2060. PMID: 31184711, PMCID: PMC6691685, DOI: 10.1210/en.2019-00367.Peer-Reviewed Original ResearchConceptsAndrogen deprivation therapyCell linesHuman peripheral blood monocytesMetastatic prostate cancerPotential treatment optionPeripheral blood monocytesCytotoxicity of macrophagesHuman monocyte cell lineProstate cancer cellsCaP cell linesMonocyte cell lineVivo mouse studiesCytotoxic activityMurine macrophage cell lineApoptosis-inducing ligandConcentration-dependent mannerDeprivation therapyClodronate liposomesTreatment optionsM1 polarizationCaP tumorsAndrogen receptorMacrophage cell lineProstate cancerImmune responseSimilar incidence of DNA damage response pathway alterations between clinically localized and metastatic prostate cancer
Kim I, Kim S, Srivastava A, Saraiya B, Mayer T, Kim W, Kim I. Similar incidence of DNA damage response pathway alterations between clinically localized and metastatic prostate cancer. BMC Urology 2019, 19: 33. PMID: 31060606, PMCID: PMC6501301, DOI: 10.1186/s12894-019-0453-9.Peer-Reviewed Original ResearchConceptsCastration-resistant prostate cancerDDR pathway alterationProstate cancerPathway alterationsMetastatic castration-resistant prostate cancerSerum prostate-specific antigenHigh-risk diseaseMetastatic prostate cancerLower overall survivalPathway gene mutationsProstate-specific antigenPotential therapeutic targetUnited States National Cancer InstituteNational Cancer InstituteCRPC patientsCancer Genome AtlasOverall survivalSimilar incidenceTumor stageUnivariate analysisCancer InstituteTherapeutic targetSpecific antigenPARP inhibitorsPathway status